BackEli Lilly and Company Overview

Eli Lilly and Company EBIT

Latest ebit for LLY.DE: $40B, below the Healthcare sector average of $1.9T.

Get informed when a big investor buys or sells

+ Follow

Quarterly EBIT

$13.38B
↑ 85.04% YoY

As of Sep 30, 2026

Annual EBIT (TTM)

$39.72B
↑ 71.03% YoY

Trailing 12 months ending Sep 30, 2026

Average EBIT (Comparison Companies)

EBIT History

EBIT Comparison

Annual EBIT Growth Rate (%)

Annual EBIT Growth (Absolute)

Eli Lilly and Company (LLY.DE) FAQ

As of the most recent data (September 2026), LLY.DE shows a EBIT of $40B. That compares with $23B in the prior-year period — up 71.0% year over year. That is below the Healthcare sector average of $1.9T. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, LLY.DE's EBIT is now $40B (was $23B) — a 71.0% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether Eli Lilly and Company is outperforming or lagging.

The Healthcare sector average EBIT is about $1.9T. Eli Lilly and Company is at $40B, which is lower that average. That is roughly 98.0% below the sector mean. Use the comparison chart on this page to see how LLY.DE stacks up against individual peers as well.

Tracking LLY.DE's ebit over time shows whether Eli Lilly and Company is scaling, shrinking, or reshaping that part of the business. The current reading is $40B That compares with $23B in the prior-year period — up 71.0% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this ebit page, Stockcircle has Eli Lilly and Company's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect EBIT (currently $40B) with ownership activity and broader fundamentals.